NovoCure Ltd. ((NVCR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a recent update, NovoCure Ltd. announced the ongoing TIGER Meso Study, officially titled ‘TTFields in General Routine Clinical Care in Patients With Pleural Mesothelioma Study.’ The study aims to gather real-life data on the use of Tumor Treating Fields (TTFields) in treating pleural mesothelioma, a rare and aggressive cancer. This research is significant as it seeks to validate the effectiveness of TTFields in routine clinical settings, potentially offering new hope for patients.
The intervention being tested is a medical device known as TTFields. This device is designed to disrupt cancer cell division, thereby inhibiting tumor growth. It is intended for use in patients with pleural mesothelioma as part of their standard clinical care.
The study is observational in nature, focusing on real-world applications of TTFields. It employs a prospective time perspective, meaning it follows patients forward in time to assess outcomes. All participants will receive standard clinical care alongside TTFields, providing insights into its practical benefits.
The study commenced on September 6, 2022, with its primary completion and estimated overall completion dates yet to be announced. The most recent update was submitted on August 18, 2025, indicating ongoing progress and data collection.
This study update could positively influence NovoCure’s stock performance by reinforcing investor confidence in the company’s innovative cancer treatment solutions. As the study progresses, it may also impact the competitive landscape, particularly if TTFields proves to be a viable treatment option in routine care.
The TIGER Meso Study is currently recruiting, with further details available on the ClinicalTrials portal.